30 March 2020

This article has been developed to offer guidance for those people who are affected by Myasthenia Gravis or Lambert-Eaton Myasthenic Syndrome.

As most patients with MG are on immunosuppressive or immunomodulatory therapies and may also have respiratory muscle weakness, there is a theoreticla concern that MG/LEMS patients may be at higher risk of contracting the infection or experiencing severe manifestations of COVID-19.